ASSESSING THE RATIONALE OF FDC CONTAINING OFLOXACIN AND AZOLES: DISSOLUTION, PERMEATION AND ANTIMICROBIAL STUDIES
Objective: To study fixed-dose combinations (FDC) of antibacterial and antiprotozoal products (ofloxacin and azoles), prescribed for the treatment of diarrhea.
Methods: Rationality of these FDC products was verified by assessing parameters such as drug content and release by assay and dissolution tests, respectively mentioned in the Indian Pharmacopoeia (IP). Amount of drug solubilized and permeated as per the Biopharmaceutics Classification System (BCS) was determined. Ex vivo permeation study was performed on the gut of goat using the everted gut sac technique. Antimicrobial efficacy in terms of minimum inhibitory concentration (MIC) was assessed using agar well diffusion method against Shigella boydii, the causative agent for diarrhea. Comparative studies were performed on an individual as well as combination doses of antibacterial and antiprotozoal products for the synergistic effects to assess the rationale of these FDC.
Results: The BCS solubility of ciprofloxacin (CPX), norfloxacin (NFX) and tinidazole (TNZ) was high in acidic medium (pH 1-5) and decreased at pH above 5. The assay studies showed that the individual drug contents of FDC were within the IP limits. In vitro dissolution results for both, individual drugs and their combination illustrated 99 % drug release within 30 min in 0.01N HCl. Ex vivo permeation of TNZ was higher than CPX and NFX in individual drugs. No significant change in the permeation rate was observed for individual drugs and their FDC. CPX and NFX exhibited more antimicrobial activity in terms of inhibitory zones than their FDC with antiprotozoal TNZ, above 2.5 µg/ml MIC. The pharmaceutical, biopharmaceutical and antimicrobial evaluation study showed the similarity of FDC with the individual drugs.
Conclusion: The study showed no significant data to justify the therapeutic advantage of FDC over individual drugs.
2. Vyas N, Gor A, Suthar J. Evaluation of prescribing pattern of fixed dose combinations of antihypertensives and antidiabetic agents. Asian J Pharm Clin Res 2017;10:164-8.
3. Yadav A, Jeenger J, Panwar D. Evaluation of rationality of fixed-dose combinations prescribed in psychiatric patients. Nat J Physiol Pharm Pharmacol 2016;6:150-4.
4. Mcgettigan P, Roderick P, Mahajan R, Kadam A, Pollock A. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDC containing non-steroidal anti-inflammatory drugs (NSAIDS), metformin, or psychotropic drugs. J Plos Med 2015;12:1-28.
5. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division. jsp?num_id=MzI1MQ== [Last accessed on 10 Jul 2019]
6. Vidyavathi M, Srividya G. A review on ciprofloxacin: dosage form perspective. Int J Appl Pharm 2018;10:6-10.
7. Thota D, Yarri SV, Vaddi P, Jillella VL. Development and validation of UV spectrophotometric methods for simultaneous estimation of ciprofloxacin and tinidazole in tablet formulation. Int Curr Pharm J 2012;1:317-21.
8. Prathyusha V, Abdul Rahaman S, Revati S, Renuka G. Development and validation of UV spectrophotometric methods for simultaneous estimation of ciprofloxacin and tinidazole in tablet dosage form. Int J Pharm Ind Res 2013;3:295-300.
9. Shrivastava D, Shrivastava A, Patel RA. Review of spectrophotometric determination of antibiotic norfloxacin. Int J Pharm Sci Res 2017;8:3619-29.
10. Chakrabarti A. Prescription of fixed dose combination drugs for diarrhoea. Indian J Med Ethics 2007;4:165-7.
11. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm [Last accessed on 10 Jul 2019]
12. https://www.who.int/medicines/news/2017/20th_essential_med-list/en/ [Last accessed on 10 Jul 2019]
13. World Health Organisation. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage form QAS/04.109/Rev.1; 2006.
14. Nayak K, Khare N, Sayare A, Ghode P, Lawrence R. New validated UV spectrophotometric methods for estimation of norfloxacin and tinidazole in bulk and tablet dosage form. Pharm Lett 2012;4:192-8.
15. The Indian Pharmacopoeia. Department of Ministry of Health and Family Welfare. Published by The Indian Pharmacopoeia Commission, Ghaziabad, 2018; Vol. I/II/III: 179-181, 1630-1631, 2750, 3381.
16. Choudhary S, Goyal A, Singh G. Dissolution development of ciprofloxacin and tinidazole in combined tablet dosage form. Int J Pharm Ther 2015;6:33-6.
17. USFDA Draft Guidance on Tinidazole; 2012.
18. Zakelj S, Sturm K, Kristl A. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 2006;313:175-80.
19. Mendesa C, Meirellesa G, Silvab M, Ponchela G. Intestinal permeability determinants of nor?oxacin in using chamber model. Eur J Pharm Sci 2018;121:236-42.
20. Kinh L, Anh D, Jovel S, Khue T. Tinidazole delivery improved by nanosized minicells originated from leuconostoc mesenteroides. Hindawi J Nanomaterials 2019:1-9. https://doi.org/10.1155/2019/7684795
21. Stahib AH, Beermann D, Harder S, Fuhr U, Liermann D. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med 1989;87:66-9.
22. Balouri M, Sadiki M, Ibnsouda S. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 2016;1:71-9.
23. Balasubramanian J, Radhika N, Badarinath AV. The crave of fixed dose combination in Indian market. Asian J Pharm Clin Res 2014;7:106-10.
This work is licensed under a Creative Commons Attribution 4.0 International License.